In This Section

PR&P Joint Virtual Issue on Neuroprotection

Neurodegeneration broadly encompasses age-dependent perturbations in neuronal, glial, and synaptic physiology that underly prototypic cognitive (e.g., Alzheimer’s) or motoric (e.g., Parkinson’s and ALS) diseases. Psychiatric comorbidities are commonly associated with these neurodegenerative disorders, further complicating diagnosis and treatment (e.g., Huntington’s disease).

This virtual issue comprises a representative selection of outstanding peer-reviewed original research and topical reviews on neurodegeneration and neuroprotection recently published in Pharmacology Research & Perspectives (PR&P) and ASPET partner journals Pharmacological Reviews, The Journal of Pharmacology and Experimental Therapeutics, and Molecular Pharmacology. Topics include modeling schemes using big data from systems pharmacology research and numerous drug discovery strategies for potential therapeutic interventions targeting amyotrophic lateral sclerosis, Alzheimer’s Disease, as well as stroke and traumatic brain injury. Additionally, this virtual issue highlights new insights into neurochemical pathways underlying neurotoxicity and endogenous neuroprotective mechanisms. Novel research on potential treatment options for movement disorders such as Parkinsonism, dystonia, and chronic pain are also presented.

The articles contained in this joint virtual issue should be of considerable interest to all investigators working to better understand neurodegenerative mechanisms and viable approaches for the development of new therapeutic interventions. We encourage our readers and potential authors to review these excellent papers as they consider venues for communicating their pharmacology research on all aspects of neurodegeneration and neuroprotection.

You can read the complete collection using the links below.

Andrew J. Lawrence
Editor-in-Chief

Michael F. Jarvis
Deputy Editor

Drug Discovery

Freely Accessible
Druggable Transcriptional Networks in the Human Neurogenic Epigenome
Gerald A. Higgins, Aaron M. Williams
Alex S. Ade, Hasan B. Alam, and Brian D. Athey
Pharmacological Reviews | First Published: September 17, 2019
Full Text | PDF | Info & Metrics | References

Open Access
5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface
Gohar Fakhfouri, Reza Rahimian, Jonas Dyhrfjeld-Johnsen, Mohammad Reza Zirak, and Jean-Martin Beaulieu
Pharmacological Reviews | First Published: June 26, 2019
Full Text | PDF | Info & Metrics | References

Freely Accessible
Derivatives of Piperazines as Potential Therapeutic Agents for Alzheimer’s Disease
Elena Popugaeva, Daria Chernyuk, Hua Zhang, Tatyana Y. Postnikova, Karina Pats, Elena Fedorova, Vladimir Poroikov, Aleksey V. Zaitsev, and Ilya Bezprozvanny
Molecular Pharmacology | First Published: January 29, 2019
Full Text | PDF | Info & Metrics | References

Open Access
Acute antioxidant and cytoprotective effects of sulforaphane in brain endothelial cells and astrocytes during inflammation and excitotoxicity
Jianxiong Liu, Giri K. Chandaka, Rong Zhang, and Helena Parfenova
Pharmacology Research & Perspectives | First Published: July 26, 2020
Full Text | PDF | Metrics

Open Access
Protection from Amyloid β Peptide–Induced Memory, Biochemical, and Morphological Deficits by a Phosphodiesterase-4D Allosteric Inhibitor
Su-Ying Cui, Ming-Xin Yang, Yong-He Zhang, Victor Zheng, Han-Ting Zhang, Mark E. Gurney, Ying Xu and James M. O’Donnell
Journal of Pharmacology and Experimental Therapeutics | First Published: September 5, 2019
Full Text | PDF | Info & Metrics | References

Open Access
T‐495, a novel low cooperative M1 receptor positive allosteric modulator, improves memory deficits associated with cholinergic dysfunction and is characterized by low gastrointestinal side effect risk
Takao Mandai, Yuu Sako, Emi Kurimoto, Yuji Shimizu, Minoru Nakamura, Makoto Fushimi, Ryouta Maeda, Maki Miyamoto, and Haruhide Kimura
Pharmacology Research & Perspectives | First Published: January 28, 2020
Full Text | PDF | Metrics

Freely Accessible
Amlexanox Inhibits Cerebral Ischemia-Induced Delayed Astrocytic High-Mobility Group Box 1 Release and Subsequent Brain Damage
Sebok Kumar Halder and Hiroshi Ueda
Journal of Pharmacology and Experimental Therapeutics | First Published: January 12, 2018
Full Text | PDF | Info & Metrics | References

Open Access
N-Phthalyl-l-Tryptophan (RG108), like Clozapine (CLO), Induces Chromatin Remodeling in Brains of Prenatally Stressed Mice
Erbo Dong, Valentina Locci, Eleonora Gatta, Dennis R. Grayson, and Alessandro Guidotti
Molecular Pharmacology | First Published: November 5, 2018
Full Text | PDF | Info & Metrics | References

Modeling

Freely Accessible
High-dimensionality Data Analysis of Pharmacological Systems Associated with Complex Diseases
Jhana O. Hendrickx, Jaana van Gastel, Hanne Leysen, Bronwen Martin, and Stuart Maudsley
Pharmacological Reviews | First Published: December 16, 2019
Full Text | PDF | Info & Metrics | References
https://doi.org/10.1124/pr.119.017921

Neurochemistry

Open Access
A Practical Review of Proteasome Pharmacology
Tiffany A. Thibaudeau and David M. Smith
Pharmacological Reviews | First Published:March 13, 2019
Full Text | PDF | Info & Metrics | References
https://doi.org/10.1124/pr.117.015370

Freely Accessible
Beyond the Ligand: Extracellular and Transcellular G Protein–Coupled Receptor Complexes in Physiology and Pharmacology
Henry A. Dunn, Cesare Orlandi, and Kirill A. Martemyanov
Pharmacological Reviews | First Published: September 12, 2019
Full Text | PDF | Info & Metrics | References

Open Access
Memantine protects thalamocortical hyper‐glutamatergic transmission induced by NMDA receptor antagonism via activation of system xc−
Motohiro Okada, Kouji Fukuyama, Yasuhiro Kawano, Takashi Shiroyama, and Yuto Ueda
Pharmacology Research & Perspectives | First Published: January 7, 2019
Full Text | PDF | Metrics

Freely Accessible
Tetrabenazine Facilitates Exocytosis by Enhancing Calcium-Induced Calcium Release through Ryanodine Receptors
Ricardo de Pascual, Nuria Álvarez-Ortego, Cristóbal de los Ríos, Gema Jacob-Mazariego, and Antonio G. García
Journal of Pharmacology and Experimental Therapeutics | First Published: June 17, 2019
Full Text | PDF | Info & Metrics | References

Freely Accessible
Pyrimidinyl Biphenylureas Act as Allosteric Modulators to Activate Cannabinoid Receptor 1 and Initiate β-Arrestin–Dependent Responses
Caitlin A. D. Jagla, Caitlin E. Scott, Yaliang Tang, Changjiang Qiao, Gabriel E. Mateo-Semidey, Guillermo A. Yudowski, Dai Lu, and Debra A. Kendall
Molecular Pharmacology | First Published: October 15, 2018
Full Text | PDF | Info & Metrics | References

Open Access
Substrate-Induced Motion between TM4 and TM7 of the Glutamate Transporter EAAT1 Revealed by Paired Cysteine Mutagenesis
Wenlong Zhang, Xiuping Zhang, and Shaogang Qu
Molecular Pharmacology | First Published: October 22, 2018
Full Text | PDF | Info & Metrics | References

Open Access
Effects of RAGE inhibition on the progression of the disease in hSOD1G93A ALS mice
Liping Liu, Kelby M. Killoy, Marcelo R. Vargas, Yasuhiko Yamamoto, and Mariana Pehar
Pharmacology Research & Perspectives | 2020, 8(4): e00636
Full Text | PDF | Metrics
https://doi.org/10.1002/prp2.636

Open Access
Leucine‐rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes
Daniela Mercatelli, Paolo Bolognesi, Martina Frassineti, Clarissa A. Pisanò, Francesco Longo, Derya R. Shimshek, and Michele Morari
Pharmacology Research & Perspectives | First Published: May 27, 2019
Full Text | PDF | Metrics

Treatments

Freely Accessible
Duloxetine Attenuates Paclitaxel-Induced Peripheral Nerve Injury by Inhibiting p53-Related Pathways
Yuting Lu, Peng Zhang, Qiuyan Zhang, Chao Yang, Yangyan Qian, Jinshuai Suo, Xinxia Tao, and Jing Zhu
Journal of Pharmacology and Experimental Therapeutics | First Published: April 1, 2020
Full Text | PDF | Info & Metrics | References

Open Access
Levodopa‐carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation
Matthew Rosebraugh, Hari V. Kalluri, Wei Liu, Charles Locke, Dilraj Sidhu, Jian‐Hwa Han, and Janet Benesh
Pharmacology Research & Perspectives | First Published: April 8, 2019
Full Text | PDF | Metrics

Freely Accessible
Dopamine Receptor Agonist Treatment of Idiopathic Dystonia: A Reappraisal in Humans and Mice
Xueliang Fan, Yuping Donsante, H. A. Jinnah, and Ellen J. Hess
Journal of Pharmacology and Experimental Therapeutics | First Published: January 18, 2018
Full Text | PDF | Info & Metrics | References